乳腺癌、前列腺癌和多发性骨髓瘤患者颌骨药物相关性骨坏死的患病率
Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma.
作者信息
Rugani Petra, Walter Christian, Kirnbauer Barbara, Acham Stephan, Begus-Nahrman Yvonne, Jakse Norbert
机构信息
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria.
Oral and Maxillofacial Surgery of the Mediplus Clinic, 55128 Mainz, Germany.
出版信息
Dent J (Basel). 2016 Sep 27;4(4):32. doi: 10.3390/dj4040032.
Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.
药物相关性颌骨坏死是恶性疾病患者抗吸收治疗的一种已知副作用。然而，确切的发病机制仍然未知，已发表的患病率显示出很大的范围。本文的目的是评估接受肠外抗吸收治疗的乳腺癌、前列腺癌和多发性骨髓瘤患者中骨坏死（ONJ）的患病率。因此，进行了PubMed搜索，分析纳入了69篇匹配文章，共29437例患者。其中描述了951例颌骨坏死病例。乳腺癌组的总体ONJ患病率为2.09%，前列腺癌组为3.8%，多发性骨髓瘤患者为5.16%。
Zotero 插件